Detalhe da pesquisa
1.
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Med Res Rev
; 42(1): 112-155, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33928670
2.
Roughness-dependent clogging of particle suspensions flowing into a constriction.
Soft Matter
; 17(31): 7252-7259, 2021 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34318863
3.
Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Br J Cancer
; 123(5): 752-761, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32541873
4.
Facile Fabrication of Flexible and High-Performing Thermoelectrics by Direct Laser Printing on Plastic Foil.
Adv Mater
; 36(15): e2307945, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100238
5.
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.
Cancer Drug Resist
; 6(4): 709-728, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38239393
6.
The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
Front Immunol
; 13: 1001161, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36268020
7.
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy.
Front Oncol
; 11: 697967, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34568028
8.
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.
Front Immunol
; 12: 737311, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34557197
9.
Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.
Cancers (Basel)
; 11(1)2019 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30650638
10.
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
Mol Oncol
; 12(6): 830-854, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603584
11.
Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
Cancer Biother Radiopharm
; 32(7): 229-238, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28910149